Treatments in Endocrinology

, Volume 3, Issue 3, pp 191–196

Effects of Oral Contraceptives on Bone Mineral Density

Authors

    • Department of Obstetrics and Gynecology ‘Piero Fioretti’University of Pisa
  • Patrizia Monteleone
    • Department of Obstetrics and Gynecology ‘Piero Fioretti’University of Pisa
  • Massimo Ciaponi
    • Department of Obstetrics and Gynecology ‘Piero Fioretti’University of Pisa
  • Alessandro Sacco
    • Department of Obstetrics and Gynecology ‘Piero Fioretti’University of Pisa
  • Andrea R. Genazzani
    • Department of Obstetrics and Gynecology ‘Piero Fioretti’University of Pisa
Review Article

DOI: 10.2165/00024677-200403030-00006

Cite this article as:
Gambacciani, M., Monteleone, P., Ciaponi, M. et al. Mol Diag Ther (2004) 3: 191. doi:10.2165/00024677-200403030-00006

Abstract

Osteoporosis is a major health problem that leads to a high incidence of spine, radial, and hip fractures. It is now well recognized that a chronically hypoestrogenic state increases bone turnover that, in turn, causes a critical decrease in bone mineral density (BMD), an important determinant of fracture risk. During the premenopausal period, hypogonadism can have deleterious effects on skeletal health by reducing peak bone mass or inducing precocious bone loss. In young women, hypothalamic amenorrhea, caused by gonado-tropin-releasing hormone pulsatility dysregulation, is often associated with bone loss.

Although the relationship between hypothalamic amenorrhea and bone density is not completely understood, the most plausible intervention for this disorder at the moment seems to be the use of hormone replacement. Oral contraceptives are associated with an improvement in BMD if assumed upon the onset of anovulatory cycles and, therefore, estrogen deficiency, but confer no benefit in healthy women with normal ovarian function. In perimenopausal oligomenorrheic women, the use of oral contraceptives seems to have bone-sparing effects.

In conclusion, the protective role of oral contraceptives on bone density is biologically plausible, since this treatment represents a replacement therapy with continuous exposure to exogenous estrogens.

Copyright information

© Adis Data Information BV 2004